Back to Report Store Home

Rheumatoid Arthritis Market to 2020 - A Crowded Market Characterized by Modest Growth

  • Published: Jan-2015
  • Report Code: GBIHC354MR
  • Report Format: pdf

Description

The burden of Rheumatoid Arthritis (RA), a chronic, progressive, and currently incurable autoimmune disease that primarily affects the joints, is considerable. It is estimated to affect approximately 4.9 million people across the major markets. It is costly to healthcare services and leads to substantial economic and quality of life impairments for patients, at least 50% of whom are unable to maintain full-time employment within 10 years of onset.

Prior to 1998, treatment options were limited to small-molecule disease-modifying therapies such as methotrexate, sulfasalazine, and anti-malarials. However, approximately 33% of all patients are unresponsive to these first-line drugs. The approval of revolutionary biological therapies, including Enbrel, Remicade, and Humira, for the treatment of patients that are refractory to methotrexate has triggered unparalleled growth in the market. Nevertheless, many patients also fail to respond to second-line therapies. In addition, there remains a significant unmet need in terms of safer drug profiles and a convenient route of administration.

Scope

  • Competition for Tumor Necrosis Factor Alpha (TNF-a) inhibitors is fierce and now dominates the second-line treatment of patients who are refractory to first-line disease-modifying therapies. In 2013, three TNF-a-targeting biologics – Humira, Remicade, and Enbrel – were ranked among the top-10 best-selling drugs in the world, with global revenues of $11.1 billion, $9.9 billion, and $8.9 billion respectively, reflecting their groundbreaking clinical and commercial success.

  • Will the leading TNF-a inhibitors continue to dominate the second-line treatment of RA?

  • Will patent expirations or emerging pipeline molecules threaten their commercial success?

  • The current pipeline is highly active and innovative with a strong biologics presence throughout, reflecting the commercial and clinical success of these molecules in the marketed products landscape.

  • Which classes of biologics are most prominent within the RA pipeline?

  • Is there strong potential for the pipeline to address unmet needs within the RA market?

  • Analysis of 506 clinical trials since 2006 identified that RA products have a high rate of attrition.

  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?

  • How do other factors, such as average trial duration and trial size influence the costs and risks associated with developing various types of RA products?

  • Over the 2013–2020 forecast period, the global RA market is expected to increase in value at a CAGR of 4.1%, from $14.3 billion to just over $19 billion. Market growth is projected to vary considerably across the eight major markets.

  • Which markets make the most significant contribution to the current market size?

  • Which factors will influence growth rates in the different major markets?

  • Will new market entrants over the forecast period lead to substantial changes in annual therapy costs?

Reasons To Buy

  • Understand the clinical context of the RA indication by considering symptoms, etiology, pathophysiology, co-morbidities and complications, epidemiology, diagnosis, and treatment options.

  • Identify therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps within the market and areas of unmet need.

  • Appreciate key RA pipeline trends in molecule type, administration route, mechanism of action, and novelty.

  • Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.

  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.

  • Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan.

  • Discover trends in licensing and co-development deals concerning RA products and identify the major strategic consolidations that have shaped the commercial landscape.

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards